Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
A Multicenter Open-Label Phase 2 Study of IMGN529 in combination with rituximab in Patients with relapsed or refractory B-Cell lymphoma and Other Forms of Non-Hodgkin's Lymphoma. Study Arms: 1) Experimental: Phase 2 IMGN529 + Rituximab
For Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL. Participants will be considered to have a relapsed disease if they showed a duration of response of at least 24 weeks after their first line of therapy. The following participants with relapsed DLBCL will be enrolled:
Wanda Burdette, RN
864-560-6810 or 864-560-6812
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.